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PURPOSE—To determine the mechanism through which topical mitomycin C prevents and treats
corneal haze after photorefractive keratectomy (PRK) and to examine the effects of dosage and
duration of exposure.
METHODS—In 224 New Zealand rabbits, −9.0 diopter PRK with mitomycin C or balanced salt
solution was performed. Haze level was graded at the slit-lamp. Rabbits were sacrificed at 4 hours,
24 hours, 4 weeks, or 6 months after surgery and immunohistochemistry was performed with TUNEL
assay, Ki67 and α-SMA.
RESULTS—TUNEL-positive apoptotic cells marginally increased in all mitomycin C groups
whereas Ki67-positive mitotic cells decreased significantly following mitomycin C application. A
greater decrease in myofibroblasts was noted with prophylactic mitomycin C treatment than
therapeutic mitomycin C treatment. There was, however, an anterior stromal acellular zone
(approximately 20% of the total stroma) in eyes treated with mitomycin C, which persisted to the
maximum follow-up of 6 months.
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CONCLUSIONS—Mitomycin C treatment induces apoptosis of keratocytes and myofibroblasts,
but the predominate effect in inhibiting or treating haze appears to be at the level of blocked
replication of keratocytes or other progenitor cells of myofibroblasts. Treatment with 0.002%
mitomycin C for 12 seconds to 1 minute appears to be just as effective as higher concentrations for
longer duration in the rabbit model. However, a persistent decrease in keratocyte density in the
anterior stroma could be a warning sign for future complications and treatment should be reserved
for patients with significant risk of developing haze after PRK.
Photorefractive keratectomy (PRK) has proven to be a safe and effective procedure to correct
low to moderate levels of myopia, hyperopia, or astigmatism. It continues to represent a good
alternative to LASIK for many patients, and in some situations, PRK remains the procedure
of choice.1 However, PRK continues to have downsides, including increased postoperative
pain, a stronger healing response, and most significantly, the possibility of subepithelial corneal
opacity or “haze” formation following corrections for high myopia.2,3
The native conformation of the extracellular matrix is altered after PRK. Along with changes
in cellular density and phenotype, there is variable production of disorganized extracellular
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matrix components and generation of myofibroblasts.4 The end result is a decrease in tissue
transparency associated with subepithelial corneal haze, which in some patients, is clinically
significant. Several different clinical factors likely contribute to haze formation including the
depth of ablation, delayed epithelial healing, and the smoothness of the stromal surface after
the ablation.5,6 Recent studies have confirmed that postoperative smoothness of the stromal
surface is an important factor contributing to subepithelial haze formation.7 In addition,
different modulators of the corneal wound healing response and potential medications have
been suggested for treatment.8–11
The use of topical mitomycin C during surface ablation procedures has gained considerable
attention over the past few years. The mitomycins are potent antibiotics that belong to the
family of anti-tumor quinolones.12 In 1956, mitomycin A and B were isolated from the broth
of Streptomyces caespitosus, and shortly thereafter mitomycin C was discovered.12 Mitomycin
C forms a covalent linkage with deoxyribonucleic acid (DNA) and inhibits DNA synthesis,
functioning as a powerful alkylating agent.12,13 At high concentrations, cellular RNA and
protein synthesis can also be suppressed.12,13 As a consequence of these cyclostatic effects,
mitomycin C is believed to trigger apoptosis and inhibit proliferation of virtually all cells which
it enters in sufficient concentrations, including corneal epithelial cells, stromal cells,
endothelial cells, conjunctival cells, Tenon’s capsule fibroblasts, and retinal pigment epithelial
cells.14–17
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The potent effects of mitomycin C on cell replication during the wound healing response gained
the attention of vision researchers and its potential benefits in preventing or inhibiting scar
formation suggested several possible applications to clinicians. Watanabe et al18 demonstrated
that conjunctival cell replication was markedly inhibited by the topical administration of
mitomycin C, suggesting potential applications during trabeculectomy surgery. Topical
mitomycin C treatment has also been used in the treatment of recurrent pterygium and
conjunctival and corneal intraepithelial neoplasia. Subsequently, topical mitomycin C
treatment was proposed as an alternative therapy for corneas with previous scar formation
secondary to refractive surgical procedures.19 In 1991, Talamo et al20 suggested the use of
topical mitomycin C as a modulator of the corneal wound healing response after excimer laser
photoablation. These investigators reported that rabbits treated with mitomycin C following
laser ablation had markedly reduced formation of subepithelial collagen. Majmudar et al19 first
proposed the use of mitomycin C to treat patients with subepithelial fibrosis secondary to
previous PRK and radial keratotomy. These authors reported a significant improvement in
corneal clarity with a single, 2-minute intraoperative application of 0.02% mitomycin C.
Intraoperative use of topical mitomycin C was subsequently used prophylactically to prevent
subepithelial haze formation following PRK. Carones et al21 reported a statistically significant
decrease in subepithelial haze formation and more accurate refractive outcomes after the
prophylactic use of 0.02% mitomycin C during PRK in a group of 60 patients with a spherical
equivalent between −6.0 and −10.0 diopters (D) of myopia. Since these early reports, many
clinicians have begun using mitomycin C prophylactically—even for low corrections.
However, several questions regarding the optimal dosage and exposure time and the long-term
safety and efficacy of topical mitomycin C treatment remain unanswered. Even the primary
mechanism of action of mitomycin C in the cornea remains uncertain.
The purpose of this study was to examine the effect of topical mitomycin C used at different
concentrations and for varying exposure times on corneal cells in situ and the efficacy of
prophylactic and therapeutic mitomycin C treatments on subepithelial corneal haze following
PRK for high myopia in a rabbit model.
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Animals—The Animal Control Committee at the Cleveland Clinic Foundation approved all
animal studies described in this work. All animals were treated in accordance with the tenets
of the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Anesthesia
was obtained by intramuscular injection of ketamine hydrochloride (30 mg/kg) and xylazine
hydrochloride (5 mg/kg). In addition, topical proparacaine hydrochloride 1% (Alcon, Ft Worth,
Tex) was applied to each eye just prior to surgery. Euthanasia was performed using an
intravenous injection of 100 mg/kg pentobarbital while the animal was under general
anesthesia.
Two hundred twenty-four 12- to 15-week-old female New Zealand white rabbits weighing 2.5
to 3.0 kg each were included in this study. One eye of each rabbit was selected at random to
be in the study. Nine groups were included (Table 1). All study and control eyes had −9.0 D
PRK with a 6.0 mm ablation zone performed with an Apex Plus Summit Laser (Alcon). The
PRK had a depth of 108 µm (421 pulses). This treatment has been shown to produce marked
subepithelial haze in 100% of rabbit eyes.4
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Three time points were examined in both prophylactic and therapeutic groups: 4 hours, 24
hours, and 4 weeks after application of mitomycin C or balanced salt solution (BSS). There
were six eyes in each group at each time point. To observe long-term effects, another time
point at 6 months was added to prophylactic group I (P-I; 0.02% mitomycin for 2 minutes) and
the control group (C). Time points following treatment were selected on the basis of peak
occurrence of the events under investigation in a previous study.4 Thus, the 4-hour time point
was selected to study the approximate peak of apoptosis, the 24-hour time point was selected
to study the approximate peak of proliferation of fibroblast cells, and the 4-week time point
was selected to study the approximate peak of myofibroblast generation.
To study the prophylactic effects of mitomycin C, PRK was performed followed by application
of mitomycin C or BSS. The prophylactic groups (Table 1) were: P-I, mitomycin C 0.02% in
BSS for 2 minutes; P-II, mitomycin C 0.02% in BSS for 1 minute; P-III, mitomycin C 0.02%
in BSS for 12 seconds; P-IV, mitomycin C 0.002% in BSS for 2 minutes; P-V, mitomycin C
0.002% in BSS for 1 minute; and P-VI, mitomycin C 0.002% in BSS for 12 seconds. The
control group, C, had BSS alone for 12 seconds, 1 minute, or 2 minutes. The contralateral eye
of each animal was an unoperated control eye.
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To generate subepithelial corneal haze to study the therapeutic effect of mitomycin C, PRK
for high myopia (−9.0 D) was performed and the rabbits followed for 4 weeks before epithelial
scrape and application of 0.05% mitomycin C for 2 minutes (TI) or BSS for 2 minutes (T2).
PRK With Mitomycin C or Balanced Salt Solution Technique—With the animal
under general and local anesthesia, a wire lid speculum was placed in the eye and a 7-mm
diameter area of epithelium overlying the pupil was removed with a #64 blade (Beaver; BectonDickinson, Franklin Lake, NJ). The −9.0 D PRK was immediately followed by the topical
application of mitomycin C or BSS to the ablated area using a soaked circular sponge (Fig 1).
The mitomycin C or BSS treatment was terminated with copious irrigation with 30 mL of BSS.
Two drops of ciprofloxacin hydrochloride 0.3% (Ciloxan, Alcon) were instilled into the eye
at the end of the procedure. Any eye that developed infiltration suggestive of infection or an
epithelial defect persisting beyond 1 week after surgery was excluded from the study and an
additional animal included in its place.
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Tissue Fixation and Sectioning—Rabbits were euthanized and the corneoscleral rims of
treated and unoperated control eyes removed with 0.12 forceps and sharp Westcott scissors.
For histological analyses, the corneas were embedded in liquid OCT compound (Sakura
FineTek, Torrance, Calif) within a 24×24×5 mm mold (Fisher, Pittsburgh, Pa). The tissue
specimens were centered within the mold so that the block could be bisected and transverse
sections cut from the center of the cornea. The mold and tissue were rapidly frozen in 2-methyl
butane within a stainless steel crucible suspended in liquid nitrogen. The frozen tissue blocks
were stored at −85°C until sectioning was performed.
Central corneal sections (7-µm thick) were cut using a cryostat (HM 505M; Micron GmbH,
Walldorf, Germany). Sections were placed on microscope slides (Superfrost Plus, Fisher) and
maintained at −85°C until staining was performed.
TUNEL Assays and Immunocytochemistry Assays—To detect fragmentation of
DNA associated with apoptosis, tissue sections were fixed in acetone at −20°C for 2 minutes,
dried at room temperature for 5 minutes, and then placed in BSS.22 A fluorescence-based
TUNEL assay was performed according to the manufacturer’s instructions (ApopTag, Cat No
S7165; Intergen, Purchase, NY). Positive control (4 hours after mechanical corneal scrape)
and negative control (unwounded) cornea slides were included in each assay. Photographs were
obtained with a fluorescence microscope (Nikon E600, Melville, NY).
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Immunocytochemistry was performed as previously reported.23 The monoclonal antibody for
either Ki67 (Zymed, San Francisco, Calif), a marker of cells in G1-M phase of mitosis, or antiα-smooth muscle actin (DAKO; Carpentaria, Calif), a marker of myofibroblasts, was placed
on the sections and incubated at room temperature for either 2 hours (anti-Ki67) or 1 hour (antiα-smooth muscle actin). The working concentrations for anti-Ki67 and anti-α-smooth muscle
actin were 214.6 mg/L (1% BSA, pH 7.4), and 85 mg/L (1% BSA), respectively. The secondary
antibody, fluorescein-conjugated donkey antimouse IgG (Jackson ImmunoResearch, West
Grove, Pa), was applied for 1 hour at room temperature. Coverslips were mounted with
Vectashield (Vector Laboratories Inc, Burlingame, Calif) containing DAPI to observe all cell
nuclei in the tissue. Negative controls with secondary antibody alone or irrelevant isotypematched antibodies were included in each experiment. The sections were viewed and
photographed with a Nikon Eclipse E800 microscope equipped with a digital SPOT camera
(Micro Video Instruments, Avon, Mass).
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Slit-lamp Microscopy Analysis and Subepithelial Haze Grading—Animals were
evaluated at the slit-lamp (Haag-Streit BM900, Haag-Streit, Switzerland) under general
anesthesia to grade subepithelial corneal haze. Corneal haze was graded according to a system
previously reported by Fantes et al24: grade 0, completely clear cornea; grade 0.5, trace haze,
seen with careful oblique illumination with slit-lamp microscopy; grade 1, more prominent
haze, not interfering with visibility of fine iris details; grade 2, mild obscuration of iris details;
grade 3, moderate obscuration of iris details and lens; and grade 4, completely opaque stroma
in the area of the ablation with no visibility of iris details.
Cell Counting for Quantitation of TUNEL Assays and Immunocytochemistry
Assays—Six corneas with each surgical procedure were used for cell counting at each time
point. In each cornea, all of the stained cells in seven non-overlapping, full-thickness columns
extending from the anterior stromal surface to the posterior stromal surface were counted by
a single observer on the section under the microscope. The diameter of each column was that
of a 400× microscope field. The columns in which counts were performed were selected at
random from the central cornea of each specimen. In sections stained for alpha smooth muscle
actin and DAPI, the counts of for α-smooth muscle actin + cells only included individual cells
that had a DAPI + nucleus.
J Refract Surg. Author manuscript; available in PMC 2009 October 2.
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Keratocyte and Myofibroblast Culture—Primary corneal keratocytes were isolated from
rabbit corneas (Pel Freeze, Rogers, Ariz) using a previously reported enzymatic method25 and
seeded in four-chamber slides (1×104 cells/chamber) or 100-mm tissue culture plates (30×104
cells/plate) and grown for 7 days in serum-free MEM medium (group I). To generate
myofibroblasts (group II), 1 ng/mL TGFβ1 (R&D Systems, Minneapolis, Minn) was added to
the plate with fresh medium and replaced at 2-day intervals for 1 to 2 weeks.
Keratocyte and myofibroblast cultures were divided into groups with or without 0.02%
mitomycin C for 2 minutes followed by copious irrigation with 200 mL of BSS. The nuclei of
keratocytes and myofibroblasts were stained with DAPI (Vector Laboratories Inc). TUNEL
assay and immunocytochemistry for α-smooth muscle actin was subsequently performed, as
described above.
STATISTICAL ANALYSIS
Data were analyzed using statistical software (Statview 4.5; Abacus Concepts, Berkeley, Calif).
Variations were expressed as standard errors of the mean (SEM). Statistical comparisons
between the groups were performed using analysis of variance (ANOVA) with the BonferonniDunn adjustment for repeated measures. All statistical tests were conducted at an alpha level
of 0.05.
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RESULTS
SUBEPITHELIAL CORNEAL HAZE (SLIT-LAMP MICROSCOPY)
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All prophylactic and therapeutic groups displayed some variability in subepithelial corneal
haze formation (Table 2). Corneal haze usually became noticeable at 2 weeks after surgery and
peaked around 4 weeks. Subepithelial corneal haze was confined to the area of laser
photoablation, with sharp demarcation between ablated and unablated stroma and independent
of the area of the epithelial removal in preparation for PRK (Fig 2). Corneal haze was
subepithelial, with occasional extension posteriorly into the stroma to a maximum of
approximately 20% depth. The BSS group had significantly (P<.001) more subepithelial
corneal haze at 4 weeks after surgery than any of the prophylactic mitomycin C groups,
regardless of mitomycin concentration or exposure time (Table 2). However, all prophylactic
mitomycin C groups had some corneas with grade 0.5 haze (trace) at 4 weeks and a few corneas
in the 0.002% mitomycin C groups with 12-second or 1-minute exposure times developed
grade 1 haze at 4 weeks after surgery. However, a statistically significant (P<.05) difference
in haze formation was observed only between prophylactic groups P-I (mitomycin C 0.02%
for 2 minutes) and P-VI (mitomycin C 0.002% for 12 seconds).
Subepithelial corneal haze tended to diminish with time after 4 weeks in all groups, including
prophylactic, therapeutic, and control. Thus, significantly less subepithelial haze was observed
in the BSS control group (C), the group with the most intense haze, at 6 months after the PRK
procedure compared to 4 weeks after surgery (P<.05). No cornea treated with prophylactic
mitomycin C had detectible subepithelial haze at 6 months.
Analysis of the therapeutic groups showed significantly (P<.05) more subepithelial corneal
haze in the BSS-treated group (T-II) than the mitomycin C-treated group (T-I) (Table 2) at 4
weeks after treatment. However, the level of subepithelial corneal haze at 4 weeks after
treatment in the mitomycin C therapeutic group (T-I) was significantly higher (P<.05) than
that at 4 weeks after surgery in any of the mitomycin C prophylactic groups (Table 2).

J Refract Surg. Author manuscript; available in PMC 2009 October 2.
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The anterior stroma of all corneas that had −9.0 D PRK with or without mitomycin C had
TUNEL-positive cells in the anterior 20% of stroma at 4 hours and 24 hours after the procedure
(Fig 3). The posterior stoma and endothelium had only rare TUNEL-positive cells, and no
differences in these areas were noted between control and treatment groups. There was a
statistically significant increase in the number of cells undergoing apoptosis in the stroma (Fig
4) in the mitomycin C groups with all concentrations and exposure times at 4 hours and 24
hours compared to the control group (P<.05). The numbers of TUNEL-positive cells in the
stroma tended to gradually decrease as the mitomycin C concentration and exposure time
decreased (see Fig 3 and Fig 4), but these decreases were not statistically significant. No
specimens from any group had TUNEL-positive cells at 4 weeks after surgery.
In the therapeutic groups, epithelial scraping with mitomycin C or BSS treatment triggered
TUNEL-positive cells in the anterior 10% to 20% of stroma, but significantly more cells
underwent apoptosis in the mitomycin C-treated group (T-I) compared to the BSS-treated
control group (T-II) (Fig 5). An attempt was also made to use double labeling with the TUNEL
assay and immunocytochemistry for α-smooth muscle actin to determine whether mitomycin
C produced more apoptosis in myofibroblasts than BSS, but the results were inconclusive (see
Fig 5). However, some TUNEL+ and α-smooth muscle actin+ cells were noted.
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CELL REPLICATION IN THE STROMA
All groups displayed very few Ki67-positive cells in the stroma at 4 hours after surgery. At 24
hours after surgery (Fig 6 and Fig 7), however, large numbers of Ki67-positive stromal cells
undergoing mitosis were present in the anterior 20% to 30% of the stroma of rabbit eyes that
had PRK followed by BSS application, with significantly fewer Ki67-positive stromal cells
undergoing mitosis in eyes that had PRK followed by mitomycin C (P<.001). The differences
between the two concentrations and three exposure times for mitomycin C were not statistically
significant, except the 0.002% mitomycin C for 12 seconds group had significantly more Ki67positive proliferating cells than the other prophylactic mitomycin C treated groups, but still
significantly less proliferating stromal cells than the BSS-treated control group (see Fig 7).
At 4 weeks, there was a decrease in Ki67-positive cells in the anterior stroma of control rabbit
eyes treated with BSS (see Fig 6). The numbers of these Ki67-positive cells was still
significantly lower in the mitomycin C-treated groups than the control BSS-treated group, but
the difference was small (see Fig 6).
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In the therapeutic groups, more Ki67-positive cell were observed in the anterior stroma of
rabbit corneas with subepithelial haze that had epithelial scrape followed by treatment with
BSS compared to those treated with mitomycin C at 24 hours (P<.001) or 4 weeks (P<.05)
after treatment.
Few Ki67-positive cells were observed in any of the groups at 6 months after surgery and no
statistically significant differences between the groups were noted (not shown).
MYOFIBROBLASTS IN THE STROMA
Alpha-smooth muscle actin-positive myofibroblasts were not identified in any groups at the
early time points (4 hours and 24 hours). Significant numbers of α-smooth muscle actinpositive cells were present in the anterior 5% of the stroma in the BSS-treated control group
at 4 weeks after surgery (Fig 8 and Fig 9). For prophylactic mitomycin C treatment, there was
a statistically significant difference between all mitomycin C-treated groups and the BSStreated control group (P<.001). No significant difference was noted between the different
mitomycin C concentrations and times, except the 0.002% mitomycin C for 12 seconds group
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(P-VI) had significantly more (P<.05) myofibroblasts at 1 month than prophylactic 0.02%
mitomycin C for 2 minutes group (P-I). The number of α-smooth muscle actin-positive cells
in group P-VI was, however, still significantly less than the BSS-treated control group C (see
Fig 9).
In the therapeutic groups, α-smooth muscle actin-positive cells were observed at 4 hours after
the epithelial scrape with mitomycin C or BSS treatment, and no statistically significant
difference was noted between the groups at this early time point. However, at 4 weeks after
treatment, there were significantly more α-smooth muscle actin-positive cells in the BSS group
than the mitomycin C group (P<.05). Some myofibroblasts persisted in the mitomycin Ctreated therapeutic group. When the therapeutic group (mitomycin C 0.02% for 2 minutes) was
compared with the corresponding prophylactic group (mitomycin C 0.02% for 2 minutes), there
were significantly more myofibroblast cells in the therapeutic group (P<.05).
At 6 months after therapeutic treatment with BSS, a highly significant decrease in the number
of α-smooth muscle actin-positive cells was noted compared to 4 weeks after treatment. No
α-smooth muscle actin-positive cells were present in the mitomycin C therapeutic treatment
group at 6 months after surgery.
KERATOCYTE CELL DENSITY
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DAPI-positive staining of cell nuclei was used to mark stromal cells and determine keratocyte
density in the anterior stroma. In all groups treated with PRK, there was a statistically
significant decrease in the keratocyte density in approximately the 20% most anterior stroma
compared to the unwounded corneas at 4 weeks after surgery (P<.05). There was, however,
significantly lower (P<.01) anterior stromal keratocyte density in approximately 20% of the
anterior stroma in corneas treated prophylactically with mitomycin C compared to BSS at 4
weeks after surgery (Fig 10). Among the prophylactic mitomycin C-treated groups, the
keratocyte density in the anterior stroma at 4 weeks tended to increase with lower
concentrations of mitomycin C and shorter exposure times, although only the 0.002%
mitomycin C for 12 seconds had significantly greater keratocyte density in the anterior stroma
than the other prophylactic groups.
At 6 months after surgery, a highly significant (P<.001) decrease in keratocyte density in the
anterior stroma extending to approximately 20% depth persisted in the mitomycin C treated
groups. For example, Figure 11 shows typical results for a cornea treated with 0.02%
mitomycin C for 2 minutes (P-I) and compared to BSS for 2 minutes (C).
IN VITRO EXPERIMENTS: APOPTOSIS IN KERATOCYTES AND MYOFIBROBLASTS
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Mitomycin C 0.02% for 2 minutes significantly increases (P<.05) the number of keratocytes
undergoing apoptosis in culture compared to BSS-treated controls (not shown). Treatment with
mitomycin C 0.02% for 2 minutes also induces apoptosis of TGFβ1-induced myofibroblasts
in culture (Fig 12).

DISCUSSION
The causes of clinically significant subepithelial corneal haze following surface ablation with
the excimer laser remain enigmatic. This complication rarely occurs in normal eyes that have
PRK corrections for <6.0 D of myopia, as the incidence increases with increasing correction
for myopia. In eyes that have not had previous surgery, the incidence does not exceed >2% to
4% of patients in most studies, even with corrections up to −10.0 to −12.0 D.26,27 The disorder
almost always occurs bilaterally in the eyes of a single afflicted patient, suggesting that there
may be underlying cellular or metabolic disorders or environmental factors in some patients
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that predispose to the condition. Recent studies in our laboratory in a rabbit animal model of
subepithelial haze4 have demonstrated that surface irregularity and associated defects in the
regenerated basement membrane are associated with development of haze after PRK,
presumably due to increased penetration of epithelium-derived transforming growth factor β,
which is important in the generation of myofibroblasts.7 Studies by Stramer et al28 have also
supported an important role for the integrity of the basement membrane in development of
subepithelial corneal haze.
The possibility of severe subepithelial corneal haze formation has tended to limit surface
ablation procedures as options for correcting high refractive errors. Alternative surface ablation
techniques have been proposed, including procedures with chemical (laser subepithelial
keratomileusis) or mechanical (Epi-LASIK) epithelial flap creation.29,30 However, a small
amount of convincing evidence shows that these procedures will be associated with less
subepithelial haze formation when used in eyes with similar levels of refractive error.31–34
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Over the past few years, intraoperative use of topical mitomycin C after PRK has been
suggested as an adjunct drug to prevent subepithelial corneal haze formation19,21 based on
experimental studies suggesting efficacy for mitomycin C in minimizing subepithelial corneal
haze formation.20,35 Subsequent clinical studies reinforced the potential benefits of mitomycin
C in preventing subepithelial corneal haze after PRK.21 Recently, Gambato et al36 reported
the results of a contralateral eye study of PRK with mitomycin C or placebo in 36 patients with
high myopia with a mean followup of 18 months (range: 12 to 36 months). The results of this
study suggested that mitomycin C was effective in reducing subepithelial corneal haze
formation after PRK in eyes with high myopia. The authors did not report any toxic side effects
from the treatments.
With these studies showing the reproducible effectiveness of mitomycin C in reducing
subepithelial corneal haze formation, topical use of the drug has rapidly grown in refractive
clinical practice, with many surgeons using prophylactic treatment in all eyes that have PRK,
or any other surface ablation technique, regardless of the level of correction. In addition, several
different protocols, involving different concentrations and exposure times, have been
suggested based on clinical observations without clear scientific support. Importantly, the
mechanism of action of mitomycin C in inhibiting subepithelial haze has not been delineated
and its effects on corneal tissues have not been examined. Of critical importance, nothing is
known about the long-term effects of mitomycin C on corneal structure and function. The
purpose of this study was to study the effects of prophylactic and therapeutic mitomycin C on
corneal cells and tissues and to better define optimal dosages and exposure times of the drug
for use in preventing subepithelial haze formation.
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The results of this study demonstrate that prophylactic or therapeutic treatment with mitomycin
C is effective in preventing or treating subepithelial haze, respectively, in the rabbit model that
closely follows the human clinical situation except that subepithelial haze formation tends to
occur at higher incidence and with more intensity in the rabbit. Prophylactic treatment was
routinely more effective than therapeutic treatment. It has been our observation that therapeutic
mitomycin C treatment is most effective when stromal opacity is simultaneously removed with
phototherapeutic keratectomy or some other surgical modality (Netto and Wilson, unpublished
data, 2004). With regards to the concentration and exposure time for prophylactic mitomycin
C, the lower concentration of 0.002% was as effective as the 0.02% concentration and the
shorter exposure times, down to 12 seconds, were as effective as the longer exposure time of
2 minutes in reducing subepithelial haze and myofibroblast density in the anterior stroma at 1
month after surgery in the prophylactic groups. The 0.002% mitomycin C for 12 seconds group
(P-VI) had significantly more (P<.05) myofibroblasts at 1 month after treatment than the 0.02%
mitomycin C for the 2 minutes group (Table 2); however, it is doubtful this difference would
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be clinically relevant. With larger numbers of animals at each time point in each prophylactic
group, statistically significant differences in subepithelial haze might have been detected
between the different concentrations of mitomycin C or exposure times, but these differences
would most likely not have been clinically relevant.
Mitomycin C appears to trigger augmented keratocyte apoptosis, as well as myofibroblast
apoptosis in the case of therapeutic treatment, in comparison to epithelial scrape alone. This
was confirmed by the in vitro experiments included in this study, corroborating the work of
Kim et al.37 However, this study demonstrates that the dominate mechanism through which
mitomycin C inhibits subepithelial haze formation is likely through inhibition of proliferation
of keratocytes, and possibly other progenitor cells, that give rise to repopulating keratocytes
and haze-associated myofibroblasts that are generated in some eyes that have high PRK.
Reduction or complete inhibition of myofibroblast regeneration results in reduced abnormal
stromal matrix deposition associated with altered transparency, as well as the diminished
transparency attributable to the myofibroblasts themselves.38,39 Variations in subepithelial
corneal haze intensity were found within each group treated with prophylactic mitomycin C,
emphasizing individual variability of the corneal wound healing response among different
animals within the same species. This same variability exists among humans, leading to the
sporadic incidence of subepithelial corneal haze following PRK.40
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An alarming finding of our study was decreased cellularity of the anterior stroma at 1 month
after treatment, also noted by Kim et al,37 that persisted in the current study out to maximum
6-month follow-up of treatment with mitomycin C after PRK compared to controls. In vivo
studies performed with confocal microscopy have reported a decrease in the keratocyte density
following excimer laser ablation without mitomycin C.41 Consistent with this, all mitomycin
C groups in the present study had a highly significant decrease in keratocytes in the anterior
stroma, corresponding to the area treated with mitomycin C, compared to the control group
treated with BSS. There were significantly more keratocytes in the anterior stroma at 1 month
and 6 months after treatment in the 0.002% mitomycin C for 12 seconds group than the other
mitomycin C-treated prophylactic groups. No corneal abnormalities were detected with the
slit-lamp in these corneas, consistent with clinical observations in patients treated with
mitomycin C after PRK over the past decade. However, even longer follow-up of patients will
be needed to ensure that acellularity does not lead to long-term opacity, melting, or other
abnormalities of the corneal stroma, or overlying epithelium modulated by keratocyte-derived
cytokines.
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A few clinical recommendations can be made based on the results of this laboratory study and
information available in the literature. First, based on the uncertainties associated with longterm diminished keratocyte density in the anterior stroma following prophylactic mitomycin
C treatment and the repeated observations by many researchers that clinically significant
subepithelial haze almost never occurs in eyes that have PRK for myopia < −6.0 D or hyperopia
< +4.0 D,3,26,27 it is our suggestion that prophylactic mitomycin C rarely be used in normal
eyes that have not had prior surgery within this range. Secondly, if humans have similar
responses to rabbits, which appears likely based on prior studies, then when prophylactic
mitomycin C is used, it appears that 0.002% concentration for 12 seconds provides nearly the
same efficacy in inhibiting subepithelial haze formation as 0.02% for 12 seconds, 1 minute, or
2 minutes, while potentially having a lesser effect on long-term keratocyte density in the
anterior stroma. Mitomycin C has been used in the cornea for 10 years without serious
complications being noted. However, reducing the dosage and exposure time to the lowest
levels that remain effective in preventing subepithelial haze is probably better for corneal
health.
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Figure 1.

Topical application of mitomycin C on the rabbit cornea using a soaked circular sponge.
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Figure 2.
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Representative slit-lamp photographs showing subepithelial haze patterns and locations
restricted to the area of corneal ablation. Faint 0.5 to 1.5 subepithelial corneal haze can be seen
in the prophylactic mitomycin C groups P-I to P-VI with differing concentrations of mitomycin
C and exposure times noted. Grade II subepithelial haze is seen in one specimen (T-1) that was
not very effectively treated with therapeutic 0.02% mitomycin C for 2 minutes. Moderate to
severe subepithelial corneal haze (grade III) can be noted in the therapeutic control group
treated with BSS (T-II) and the prophylactic control group (C). Note that the subepithelial haze
tends to terminate exactly at the margin of the excimer laser ablation (arrows in C) (original
magnification ×10).
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Figure 3.

NIH-PA Author Manuscript

TUNEL assay for apoptotic cells 4 hours after surgery of the central cornea from rabbits that
had −9.0 D PRK for myopia followed by mitomycin C or BSS application. Different
concentrations and exposure times of mitomycin C are indicated. These are representative
results for each group. Cell nuclei are stained blue with DAPI and TUNEL-positive cells are
stained red (arrows) (original magnification ×200).
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Figure 4.

Quantitation of TUNEL-positive apoptotic cells in the anterior stroma (per 400× column) at 4
hours after laser surgery in all prophylactic and therapeutic mitomycin C groups and the control
(BSS) group. *, **, *** are used to indicate groups that are significantly different from the
control group. In addition, * is significantly different from **, * is significantly different from
***, and ** is significantly different from ***.
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Figure 5.
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TUNEL assay and α-smooth muscle actin double-staining of the central rabbit corneas at 4
hours after epithelial scrape followed by mitomycin C or BSS application in eyes that had −9.0
D PRK 4 weeks earlier with development of significant subepithelial corneal haze (therapeutic
treatment with mitomycin C or BSS). All cell nuclei are stained blue with DAPI. TUNELpositive cells are stained red (arrows) and α-smooth muscle actin-positive cells are stained
green (arrowheads). Overall, significantly more TUNEL-positive cells were noted in A) group
T-I than in B) group T-II (original magnification ×200).
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Figure 6.

Immunohistochemical Ki67 staining to detect cell mitosis in the central cornea in eyes that had
−9.0 D PRK for myopia followed by mitomycin C or BSS application at 24 hours or 4 weeks
after treatment. There is marked cell proliferation (arrowheads) in the anterior stroma in the
BSS group (C) at 24 hours, with some still detectable 4 weeks after treatment. Minimal
proliferation cells in the anterior stroma are noted in corneas treated with 0.02% mitomycin C
for 2 minutes (P-I) at 24 hours after treatment. In corneas treated with 0.002% mitomycin C
for 12 seconds (P-VI), there are more anterior stromal cells undergoing mitosis at 24 hours
after treatment than the higher concentration mitomycin C group, but still far fewer than in the
control group (original magnification ×200).
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Figure 7.

Quantitation of Ki67-positive cells in the anterior stroma (per 400× column) at 24 hours after
laser surgery in prophylactic and therapeutic mitomycin C-treated groups and the BSS-treated
control group. *, **, *** are used to indicate groups that are significantly different from the
control group. In addition, * is significantly different from **, * is significantly different from
***, and ** is significantly different from ***.
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Figure 8.
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Immunohistochemical staining for α-smooth muscle actin in the central cornea of
representative sections of the different groups at 4 weeks after surgery. Cells nuclei are stained
blue with DAPI and α-smooth muscle actin-positive myofibroblasts are stained green (arrows).
Note that in mitomycin C-treated corneas myofibroblasts lie beneath an acellular to paucicellular zone of anterior stroma whereas in BSS-treated corneas (either therapeutic control
group T-II or PRK control) the myofibroblasts are localized immediately beneath the
epithelium. Also note that more DAPI stained nuclei are present in the anterior stroma of all
of the prophylactic group corneas treated with 0.002% mitomycin C (P-IV, P-V, and P-VI)
compared to the corneas treated with 0.02% mitomycin C (P-I, P-II, and P-III) (original
magnification ×400).
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Figure 9.

Quantitation of α-smooth muscle actin-positive cells in the anterior stroma (per 400× column)
at 4 weeks after laser surgery in prophylactic and therapeutic mitomycin C groups and the BSStreated controls. *, **, *** are used to indicate groups that are significantly different from the
control group. In addition, * is significantly different from **, * is significantly different from
***, and ** is significantly different from ***.
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Figure 10.

Quantitation of DAPI-positive cells in the anterior stroma (per 400× column) at 4 weeks after
laser surgery in prophylactic and therapeutic mitomycin C-treated groups and BSS-treated
control groups. *, **, *** are used to indicate groups that are significantly different from the
control group. In addition, * is significantly different from **, * is significantly different from
***, and ** is significantly different from ***.

NIH-PA Author Manuscript
J Refract Surg. Author manuscript; available in PMC 2009 October 2.

Netto et al.

Page 23

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 11.

DAPI staining of cell nuclei in the central corneas from rabbits at 6 months after −9.0 D PRK
and prophylactic treatment with A) 0.02% mitomycin C or B) BSS for 2 minutes. Note the
markedly diminished keratocyte density in the anterior stroma of the cornea after mitomycin
C treatment (original magnification ×400).
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Figure 12.

Mitomycin C-induced apoptosis of myofibroblasts in vitro. A) Keratocytes cultured in the
absence of TGFβ1. Nuclei stain with DAPI, with no detectible α-smooth muscle actin-positive
cells. B) Myofibroblasts generated in the presence of TGFβ1 stain green for α-smooth muscle
actin, with nuclei staining with DAPI. C) After treatment of myofibroblasts with 0.02%
mitomycin C for 2 minutes, cells undergo triple staining—immunohistochemistry for α-smooth
muscle actin, TUNEL assay, and DAPI staining. Cells are shrunken and the nucleus of one cell
(arrow) is stained with the TUNEL assay.
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—

—

—

0.002% for 12 s

0.002% for 2 min

0.02% for 12 s

0.02% for 1 min

0.02% for 2 min

BSS 12 s to 2 min

—

—

—

—

—

—

—

BSS

—

—

MMC 0.02% for 2 min

—

—

—

—

—

Epithelial Scrape +
MMC

Previous PRK Correction
(4 weeks prior) Followed by

PRK Correction Immediately
Followed by

MMC

Therapeutic Group

Prophylactic Group

—

BSS for 2 min

—

—

—

Epithelial Scrape +
BBS
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3 (50)

0.5

4

3

2

1

3 (50)

P-I
(MMC 0.02%
2 min)

0

Degree
of Haze
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Table 2

3 (500)

3 (50)

P-II
(MMC 0.02%
1 min)

4 (66.6)

2 (33.3)

P-III
(MMC 0.02%
12 s)

4 (66.6)

2 (33.3)

P-IV
(MMC 0.002%
2 min)

1 (16.6)

3 (50)

2 (33.3)

P-V
(MMC 0.002%
1 min)

Groups (n, %)

2 (33.3)

3 (50)

1 (16.6)

P-VI
(MMC 0.002%
12 s)

2 (33.3)

3 (50)

1 (16.6)

T-I
(ES+MMC
0.02% 2 min)

3 (50)

2 (33.3)

1 (16.6)

T-II
(ES+BSS)
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Corneal Haze Grading With Slit-lamp Microscopy at 4 Weeks After Treatment

1 (16.6)

2 (33.3)

2 (33.3)

1 (16.6)

C
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